Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate-Reference-Cited by-同舟云学术

Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate

Published:2014-09-09 Issue:18 Volume:57 Page:7509-7522
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Washburn William N.¹,Manfredi Mark¹,Devasthale Pratik¹,Zhao Guohua¹,Ahmad Saleem¹,Hernandez Andres¹,Robl Jeffrey A.¹,Wang Wei¹,Mignone James¹,Wang Zhenghua¹,Ngu Khehyong¹,Pelleymounter Mary Ann¹,Longhi Daniel¹,Zhao Rulin¹,Wang Bei¹,Huang Ning¹,Flynn Neil¹,Azzara Anthony V.¹,Barrish Joel C.¹,Rohrbach Kenneth¹,Devenny James J.¹,Rooney Suzanne¹,Thomas Michael¹,Glick Susan¹,Godonis Helen E.¹,Harvey Susan J.¹,Cullen Mary Jane¹,Zhang Hongwei¹,Caporuscio Christian¹,Stetsko Paul¹,Grubb Mary¹,Maxwell Brad D.¹,Yang Hong¹,Apedo Atsu¹,Gemzik Brian¹,Janovitz Evan B.¹,Huang Christine¹,Zhang Lisa¹,Freeden Chris¹,Murphy Brian J.¹

Affiliation:

1. Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate Optimization Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New...

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm500026w

Reference31 articles.

1. World Health Organization Global Health Observatory (GHO) Web site.http://www.who.int/gho/ncd/risk_factors/obesity_text/en/(accessed Oct 18, 2013) .

2. Pharmacotherapy of Obesity: Clinical Treatments and Considerations

3. Compliance, Behavior Change, and Weight Loss With Orlistat in an Over-the-Counter Setting

4. Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men

5. Lack of an Effect of a Novel β3-Adrenoceptor Agonist, TAK-677, on Energy Metabolism in Obese Individuals: A Double-Blind, Placebo-Controlled Randomized Study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring monocyclic core: Discovery of pyrrol-2-one derivatives as a new series of potent MCHR1 antagonists with in vivo efficacy;European Journal of Medicinal Chemistry;2024-10

2. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

3. Fluorinated Cycloalkyl Building Blocks for Drug Discovery;ChemMedChem;2022-10-05

4. Cyclobutanes in Small‐Molecule Drug Candidates;ChemMedChem;2022-03-29

5. Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design;Journal of Medicinal Chemistry;2021-09-30